No Data
No Data
Denali Therapeutics Shares Are Trading Higher. The Stock May Be Moving on Continued Strength After Announcing on Thursday It Began Its Phase 2a Study of LRRK2 Inhibitor BIIB122 for LRRK2-associated Parkinson's Disease With Its First Participant Dosed.
Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report?
Express News | Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of Lrrk2 Inhibitor, Biib122, in Lrrk2-Associated Parkinson’s Disease
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson's Disease
Denali Therapeutics Management to Meet With B. Riley
B.Riley Financial Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $38